Video

Dr. Voorhees on the Benefit of Monoclonal Antibodies in Myeloma

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Peter Voorhees, MD, a myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses the benefit of monoclonal antibodies in multiple myeloma.

With regard to the existing FDA approved monoclonal antibodies, is that they can readily be added to standard-of-care backbone regimens used in multiple myeloma with good tolerability and a clear improvement in depth of response and progression-free survival (PFS), says Voorhees. The addition of elotuzumab (Empliciti), a monoclonal antibody directed against the SLAMF7 receptor, to the lenalidomide (Revlimid)/dexamethasone backbone led to increased PFS. More recently, when elotuzumab was added to the pomalidomde (Pomalyst)/dexamethasone backbone, an improved depth of response and PFS was observed. The space has seen an uptick in the use of elotuzumab in combination with pomalidomide and dexamethasone based on those data, concludes Voorhees.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine